In This Issue

1655  In This Issue of Diabetes Care

Presidential Address

1657  2016 Presidential Address: Diabetes at 212°—Confronting the Invisible Disease
  D. Schatz

Clinical Care/Education/Nutrition/Psychosocial Research

1664  Failure in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose
  W. Hoo, S. Gitelman, L.A. DiMeglio, O. Boulware, and C.J. Greenbaum, for the Type 1 Diabetes TrialNet Study Group

1671  An Evaluation of Recurrent Diabetic Ketoacidosis, Fragmentation of Care, and Mortality Across Chicago, Illinois
  J.A. Mays, K.L. Jackson, T.A. Derby, J.J. Behrens, S. Goel, M.E. Molitch, A.N. Kho, and A. Wallia

1677  Lack of Independent Association Between Fatty Pancreas and Incidence of Type 2 Diabetes: 5-Year Japanese Cohort Study
  H. Yamazaki, T. Tsuibo, A. Katanuma, Y. Kodama, S. Tauchi, M. Doheke, and H. Maguchi

1684  Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease

1693  Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

1702  Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
  C. Mathieu, B. Zinnman, J.U. Hemmingson, V. Woo, P. Colman, E. Christiansen, M. Linder, and B. Bode, for the ADJUNCT ONE Investigators

1711  Specialist-Led Diabetes Registries and Prevalence of Poor Glycemic Control in Type 2 Diabetes: The Diabetes Registry Outcomes Project for A1C Reduction (DROP A1C)
  R. Aronson, N. Orzech, C. Ye, R.E. Brown, R. Goldenberg, and V. Brown

1718  Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
  S. Hadjadj, J. Rosenstock, T. Meinecke, H.J. Woerle, and U.C. Broedl

1729  Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease
  G. Ruiz-Hurtado, L.M. Rulope, A. de la Sierra, P. Sarafidis, J.J. de la Cruz, M. Gorostidi, J. Segura, E. Vinyoles, and J.R. Banegas

Epidemiology/Health Services Research

1738  Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

1745  Longitudinal Associations of Exposure to Perfluoroalkylated Substances in Childhood and Adolescence and Indicators of Adiposity and Glucose Metabolism 6 and 12 Years Later: The European Youth Heart Study
  S.L. Domazet, A. Græntved, A.G. Timmermann, F. Nielsen, and T.K. Jensen

1752  Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease
  M. Liang, J.W. McEvoy, T. Chen, A.R. Sharrett, and E. Selvin

Emerging Technologies and Therapeutics

1768  Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial
  C.H. Wysham, L. MacConell, and E. Hardy

Pathophysiology/Complications

1787  Differences in Regional Brain Responses to Food Ingestion After Roux-en-Y Gastric Bypass and the Role of Gut Peptides: A Neuroimaging Study

1796  Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes

1804  Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects

Cardiovascular and Metabolic Risk

1811  A Common Gene Variant in Glucokinase Regulatory Protein Interacts With Glucose Metabolism on Diabetic Dyslipidemia: the Combined CODAM and Hoorn Studies

1818  Intensive Glycemic Therapy in Patients With Type 2 Diabetes on β-Blockers
  T. Tsujimoto, T. Sugiyama, M. Noda, and H. Kajio

Novel Communications in Diabetes

1827  Serum Fatty Acid Binding Protein 4 (FABP4) Predicts Pre-eclampsia in Women With Type 1 Diabetes
  A.C. Wotherspoon, I.S. Young, D.R. McCance, C.C. Patterson, M.J.A. Mares, D.W.M. Pearson, J.D. Walker, and V.A. Holmes, for the Diabetes and Pre-eclampsia Intervention Trial (DAPIT) Study Group
Review
1830  Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities
G. Musso, M. Cassader, S. Cohnhey, F. De Michieli, S. Pinach, F. Saba, and R. Gambino

Erratum
1846  Erratum. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

Issues and Events
1847  Issues and Events

e-Letters – Observations
e163  Effect of Regular Exercise Commenced in Early Pregnancy on the Incidence of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Randomized Controlled Trial
C. Wang, Y. Wei, X. Zhang, Y. Zhang, Q. Xu, S. Su, L. Zhang, C. Liu, Y. Feng, C. Shou, K.J. Guelf, J.P. Newnham, and H. Yang

e165  A Case of Euglycemic Diabetic Ketoacidosis Following Long-term Empagliflozin Therapy
P.D. Farjo, K.M. Kidd, and J.L. Reece

e167  Subjects With Extreme-Duration Type 1 Diabetes Exhibit No Structural or Functional Abnormality on Cardiac MRI
O. Aghar, C. Miller, S. Roy, M. Schmitt, and R.A. Malik

e169  Impact of the Gather mHealth System on A1C: Primary Results of a Multisite Randomized Clinical Trial Among People With Type 2 Diabetes in India
N.J. Kleinman, A. Shah, S. Shah, S. Phatak, and V. Viswanathan

e171  hs-CRP Predicts Improvement in Depression in Patients With Type 1 Diabetes and Major Depression Undergoing Depression Treatment: Results From the Diabetes and Depression (DAD) Study

e174  A Smartphone Application to Deliver a Treat-to-Target Insulin Titration Algorithm in Insulin-Naive Patients With Type 2 Diabetes: A Pilot Randomized Controlled Trial

e177  International Comparison of Smoking and Metabolic Control in Patients With Type 1 Diabetes

e179  Abdominal Obesity Is More Closely Associated With Diabetic Kidney Disease Than General Obesity
J. Hu, S. Yang, A. Zhang, P. Yang, X. Cao, X. Li, R. Goswami, Y. Wang, T. Luo, K. Liao, Q. Cheng, X. Xiao, and Q. Li

e-Letters – Comments and Responses
e181  Comment on Narayan. Type 2 Diabetes: Why We Are Winning the Battle but Losing the War? 2015 Kelly West Award Lecture. Diabetes Care 2016;39:653–663
G. Reaven

e182  Response to Comment on Narayan. Type 2 Diabetes: Why We Are Winning the Battle but Losing the War? 2015 Kelly West Award Lecture. Diabetes Care 2016;39:653–663
K.M.V. Narayan

e183  Comment on Almurdhi et al. Reduced Lower-Limb Muscle Strength and Volume in Patients With Type 2 Diabetes in Relation to Neuropathy, Intramuscular Fat, and Vitamin D Levels. Diabetes Care 2016;39:441–447
G. Treiber, I. Boulton-Blanco, M. Hugo, E. Pujol, I. Redonnet-Vernhet, S. Cambos, and V. Rigalleau

e184  Response to Comment on Almurdhi et al. Reduced Lower-Limb Muscle Strength and Volume in Patients With Type 2 Diabetes in Relation to Neuropathy, Intramuscular Fat, and Vitamin D Levels. Diabetes Care 2016;39:441–447
M.M. Almurdhi, N.D. Reeves, F.L. Bowling, A.J.M. Boulton, M. Zejierska, and R.A. Malik

e186  Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973–981
L. Monnier, C. Colette, and D.R. Owens

e188  Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973–981
K.D. O'Brien, I.B. Hirsch, M.C. Riddle, and J.L. Probstfield, for the FLAT-SUGAR Trial Investigators

e189  Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424–1430
Z. Aryan, S. Noshad, M. Afnarideh, and A. Esteghamati

e190  Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424–1430
S. Sharif, Y. van der Graaf, H.M. Nattohe, H.W. de Valk, F.L.J. Visseren, and J. Westerink, on behalf of the SMART Study Group

e192  Comment on Rickels et al. Insulins Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:264–270
A.J. Munoz, S. Girish, and M.B. Winder

e193  Response to Comment on Rickels et al. Insulins Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:264–270

Cover: Lightning storm over Bell Rock, Arizona, America, USA. By DeepDesertPhoto. © Getty Images. For more information, please visit gettyimages.com.